Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06776588
Recruiting Not applicable

Study on the Diagnosis of Ground-glass Lung Cancer by Microwave Ablation Combined With Puncture Biopsy

NCT06776588 · tracked via the Priya Life Science China tracker
Sponsor
Beidahuang Industry Group General Hospital
Phase
Not applicable
Started
2025-01-15
Last updated
2025-11-24

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Microwave ablation combined with biopsy

Microwave ablation combined with biopsy: CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.

Study summary

This study is a multicenter study. It plans to screen 200 patients with pulmonary nodule lesions with ground glass as the main body, take CT thin-layer scanning 3D reconstruction, apply AI and fragment omics technology to evaluate the risk of malignant transformation of pulmonary nodules, and use microwave ablation to treat pulmonary nodules and combine intraoperative rapid pathology technology to determine the nature of puncture tissue and the degree of ablation, and then explore the optimal ablation time and ablation power.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≤ 75 years; 2. GGN patients with the maximum axial diameter of the lesion in the lung window ≤ 3 cm; 3. Refusing radical surgery or being unable to tolerate surgical treatment; 4. Normal coagulation function, platelet count ≥ 60 × 109 /L; 5. ECOG score ≤ 2 points; Exclusion Criteria: 1. Patients with the maximum axial diameter of the lesion in the lung window greater than 3 cm 2. Platelets \<50×109 /L 3. Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term 4. Severe chronic obstructive pulmonary disease, emphysema, pulmonary fibrosis and pulmonary hypertension 5. Patients whose anticoagulant therapy or antiplatelet drugs have been discontinued for less than 5 days before ablation 6. Patients with severe heart, liver, kidney and brain dysfunction 7. Patients with severe anemia, dehydration and cachexia that cannot be corrected or improved in the short term 8. Patients with an estimated survival period of less than 6 months

Primary outcome measure(s)

  • Local contral rate — up to 36 months
    LCR is the rate of CR, PR plus SD
  • Recurrence-free survival — up to 36 months
    It estimates the recurrence-free rate of patients who have already survived, with no history of metastasis, a certain period of time.
  • Overall Survival — up to 36 months
    Defined as the time from randomization to death from any cause.

Trial sites (1)

FacilityCityRegionStatus
Beidahuang Industry Group General Hospital Harbin Heilongjiang Recruiting

Other trials for the same condition

Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer Recruiting
GPC3/Mesothelin-CAR-γδT Cells Against Cancers Recruiting
To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors Starting soon
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma Recruiting
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06776588 on ClinicalTrials.gov ↗ ← All trials in China